J&J’s Tecvayli Could See More Uptake With Data In Earlier Myeloma Treatment

 
• By Alaric DeArment
  
J&J announced topline results from the MajesTEC-3 trial in relapsed/refractory multiple myeloma patients with one to three prior lines of therapy. (Alaric DeArment)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D